Cover Image
市場調查報告書

肺高血壓 (PH) 的預測:主要8大市場

Pulmonary Hypertension Forecast in 8 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 339836
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
肺高血壓 (PH) 的預測:主要8大市場 Pulmonary Hypertension Forecast in 8 Major Markets 2015-2025
出版日期: 2015年08月01日 內容資訊: 英文 50 Pages
簡介

肺高血壓 (PH) 是以心導管法測量,肺動脈壓25mmHg以上的症狀。

本報告提供主要8大市場 (美國,法國,德國,義大利,西班牙,英國,巴西,日本) 的肺高血壓 (PH) 之目前患者數 (性別,年齡世代別) 調查分析,提供您目前得病率,加上危險因素,疾病診斷與預後,主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

  • 肺高血壓 (PH) 的血液循環動態定義

變異:地區/各民族

疾病預後與臨床經過

疾病相關的主要併發症/症候

患者數的定量化方法

肺高血壓 (PH) 的得病率top line

肺高血壓 (PH) :數據點分類

肺動脈高血壓 (PAH)

  • 肝肺症候群造成的PAH
  • 先天性心臟病造成的PAH
  • 綜合組織疾病造成的PAH
  • PAH相關的主要併發症

慢性血栓栓塞性肺高血壓 (CTEPH)

  • CTEPH:各NYHA功能級
  • CTEPH:操作狀態別
  • CTEPH相關的主要併發症

視網膜分支靜脈阻塞症 (BRVO)

  • BRVO的併發症

參考文獻

附錄

目錄
Product Code: PULH0010815

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Pulmonary Hypertension in 8 Major Markets

Pulmonary Hypertension (PH) is a condition in which pulmonary arterial pressure is 25 mmHg or greater, measured via a cardiac catheterisation. There is a number of underlying causes for this syndrome and can be groups into different classifications according to the Dana Point. This report provides the current prevalent population for PH across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of PH. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of PH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PH include:

  • COPD
  • Fibrotic Diseases
  • Cardiovascular Diseases
    • Valvular Dysfunction
    • Congenital Heart Disease
  • Diabetes
  • Thyroid Disease
  • Deep Vein Thrombosis (DVT) and Thrombotic Events
  • Obstructive Sleep Apnoea (OSA)
  • Schistosomiasis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global PH's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of PH and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on PH's prevalent population.
  • Identify sub-populations within PH which require treatment.
  • Gain an understanding of the specific markets that have the largest number of PH patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors and Prevention

Diagnosis of the Disease

  • Haemodynamic definitions of Pulmonary Hypertension

Variation by Geography /Ethnicity

Disease Prognosis and Clinical Course

Key Co-Morbid Conditions / Features Associated with the Disease

Methodology for Quantifications of Patient Number

  • Additional Data Available on Request

Top Line Prevalence for Pulmonary Hypertension

PH by Dana Point Classification Grouping

  • PH by Dana Point Grouping

Pulmonary Arterial Hypertension

  • PAH caused by Portopulmonary Hypertension
  • PAH caused by Congenital Heart Disease
  • PAH caused by Connective Tissue Disease
  • Significant Co-morbid Conditions Associated with PAH

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

  • CTEPH by NYHA Functional Class
  • CTEPH by Operable Status
  • Significant Co-morbid Conditions Associated with CTEPH

Abbreviations and Acronyms used in the Report

Other Black Swan Analysis Publications

Patient Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables and Figures

  • Dana Point Clinical Classification of Pulmonary Hypertension
  • Haemodynamic Definitions of Pulmonary Hypertension
  • Functional Classification of Pulmonary Hypertension by NYHA Class
  • Prevalence of PH, total (000s)
  • Prevalence of PH, males (000s)
  • Prevalence of PH, females (000s)
  • PH by Main DANA Grouping, total (000s)
  • PAH by NYUHA Class at Presentation, total (000s)
  • PAH by Underlying Aetiology, total (000s)
  • PAH - Severity of Right Ventricle Enlargement (000s)
  • Idiopathic PAH by NYHA class, total (000s)
  • Portopulmonary Hypertension by NYHDA Class, total (000s)
  • PAH Caused by Congenital Heart Disease by NYHDA class, total (000s)
  • PAH Caused by Connective Tissue Disease by NYHDA class, total (000s)
  • Prevalence of Hypertension in Patients with PAH, total (000s)
  • Prevalence of Diabetes in Patients with PAH, total (000s)
  • Prevalence of Ischemic Heart Disease in Patients with PAH, total (000s)
  • Prevalence of Thyroid Disease in Patients with PAH, total (000s)
  • Prevalence of Obstructive Sleep Apnoea in Patients with PAH, total (000s)
  • Prevalence of Obstructive Airway Disease in Patients with PAH, total (000s)
  • CTEPH by NYHA class, total (000s)
  • CTEPH Patients by Operable Status, total (000s)
  • Prevalence of COPD in Patients with CTEPH, total (000s)
  • Prevalence of Thrombophilic Disorder in Patients with CTEPH, total(000s)
  • Prevalence of Varicose Veins in Patients with CTEPH, total (000s)
  • Prevalence of Confirmed Previous Acute PE in Patients with CTEPH, total (000s)
  • Abbreviations and Acronyms used in the Report
  • USA Prevalence of PH by 5-yr age cohort, males (000s)
  • USA Prevalence of PH by 5-yr age cohort, females (000s)
  • France Prevalence of PH by 5-yr age cohort, males (000s)
  • France Prevalence of PH by 5-yr age cohort, females (000s)
  • Germany Prevalence of PH by 5-yr age cohort, males (000s)
  • Germany Prevalence of PH by 5-yr age cohort, females (000s)
  • Italy Prevalence of PH by 5-yr age cohort, males (000s)
  • Italy Prevalence of PH by 5-yr age cohort, females (000s)
  • Spain Prevalence of PH by 5-yr age cohort, males (000s)
  • Spain Prevalence of PH by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of PH by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of PH by 5-yr age cohort, females (000s)
  • Brazil Prevalence of PH by 5-yr age cohort, males (000s)
  • Brazil Prevalence of PH by 5-yr age cohort, females (000s)
  • Japan Prevalence of PH by 5-yr age cohort, males (000s)
  • Japan Prevalence of PH by 5-yr age cohort, females (000s)
Back to Top